Last reviewed · How we verify

AeroLEF

YM BioSciences · Phase 2 active Small molecule

AeroLEF is a liposome-encapsulated formulation of budesonide, a corticosteroid that reduces inflammation.

AeroLEF is a liposome-encapsulated formulation of budesonide, a corticosteroid that reduces inflammation. Used for Treatment of acute asthma exacerbations.

At a glance

Generic nameAeroLEF
Also known asLiposome-Encapsulated Fentanyl
SponsorYM BioSciences
Drug classCorticosteroid
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 2

Mechanism of action

The liposome-encapsulated formulation of AeroLEF allows for targeted delivery of budesonide to the lungs, reducing systemic side effects and increasing local efficacy. This targeted delivery enables AeroLEF to effectively reduce inflammation in the lungs, making it a potential treatment for various respiratory conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: